Furthermore, D,L-lysine-acetylsalicylate glycine (LASAG) a water-soluble salt of ASA (licensed as Aspirin i.v.®) was shown to decrease activation of promoter constructs of NF-κB-dependent genes for IL-6 and IL-8 and to improve the time to alleviation of influenza symptoms in hospitalized patients in a phase II clinical trial (48). This evidence concerns the gene CXCL8 and influenza.